Oct 26, 2012
As the first generation of biologic therapies lose their patent protection, what is the outlook for subsequent-entry biologics (SEBs) on the Canadian market? In a new discussion paper, Environics' Group VP of Health & Pharma, Otto Akkerman, describes the opportunities and challenges for makers of SEBs.
Download a PDF of the paper here. (You will be asked to share your name and email.)